Growth Drivers
According to the World Health Organization, about 38.4 million people worldwide were living with HIV in 2021. Hence, there has been going numerous trials to check the efficiency of triptorelin in HIV patient. However, even though this treatment is not widely used in HIV patients, owing to the ongoing research & development and huge investment from the pharmaceutical organization for the same, triptorelin treatment is estimated to be used to treat such patients during the forecast timeframe.
The second most frequently diagnosed cancer and the fifth highest cause of cancer death in males globally is considered to be prostate cancer, with a poised 1,414,000 new cancer cases and 375,304 deaths in 2020. The hormone testosterone is required for prostate cancer to develop. The testicles in men produce almost all of the testosterone. Triptorelin inhibits testosterone production in the testicles, lowering testosterone levels and slowing or halting the proliferation of cancer cells.
According to the World Health Organization, globally about 10% or 190 million women or girls of reproductive age are affected by endometriosis. It causes life-impacting pain in women during sexual intercourse, periods, bowel moment, and more. Hence, its treatment is necessary. Therefore, the use of triptorelin is growing since it has been proven effective with an acceptable safety profile. Also, since it has positive results on the reproductive part of the women, the problem in becoming could be diagnosed.
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
5.4% |
Base Year Market Size (2024) |
USD 11.1 billion |
Forecast Year Market Size (2037) |
USD 21.99 billion |
Regional Scope |
|
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?